STAT+: Roche shortens delivery time for multiple sclerosis drug from hours to minutes in trial
For people living with multiple sclerosis, slowing or stopping this chronic and debilitating neurological disease…
Category: biotechnology
STAT+: Flagship recruits former BMS, Celgene R&D chief Rupert Vessey
After leaving his post as the head of research at Bristol Myers Squibb, Rupert Vessey…
There’s a bill well-suited for drug shortage reforms, but Congress isn’t interested
WASHINGTON — Congress is considering a must-pass pandemic preparedness bill that presents a good opportunity…
STAT+: Europe issues maximum antitrust fine of $475 million to Illumina over Grail deal
LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to…
STAT+: How are insurers handling the Alzheimer’s drug Leqembi and related scans?
WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to…
STAT+: Eisai executive who helped lead development of Alzheimer’s drug to retire
Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global…
FDA approves first Alzheimer’s therapy shown to clearly slow cognitive decline
The Food and Drug Administration on Thursday granted full approval to the first therapy for…
STAT+: What to know about this summer’s landmark Wegovy heart health study
At some point this summer, the drugmaker Novo Nordisk will release results from a closely…
STAT+: With some savvy bets, a dynamic duo makes Eli Lilly one of pharma’s biggest success stories
The partnership that would shape Eli Lilly into one of the biggest success stories in…
STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
For Duchenne moms who pushed for cures, new breakthrough therapy can’t rebuild what’s lost
Pat Furlong was sitting in her home office in Middletown, Ohio, last Thursday, refreshing a…
STAT+: BioMarin wins approval for gene therapy to treat hemophilia A
The Food and Drug Administration on Thursday approved a gene therapy to treat people with…
Listen: Novavax’s CEO promises a turnaround & how Lilly roiled the obesity market
Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing…
STAT+: Alkermes shareholders re-elect directors, rebuffing effort by hedge fund Sarissa
Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious…
STAT+: Moonlake’s less-than-transparent data disclosures produced a cash windfall. Risks remain
For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from…
STAT+: Illumina to lay off 10% of research and development team in bid to cut costs by $100 million
SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing…
STAT+: Shareholders elect director’s romantic partner to Biogen’s board
Biogen shareholders voted to add biotech executive Susan Langer, who is the romantic partner of…
STAT+: In setback, Pfizer abandons one weight-loss pill and bets on another
Pfizer said Monday that it had discontinued clinical trials of a once-daily weight-loss pill whose…
STAT+: As demand for Covid shots wanes, Moderna seeks its next success
Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight…
STAT+: EU poised to reject Amylyx’s ALS drug, as the company vows an appeal
LONDON — European regulators are on the verge of rejecting an ALS drug from Amylyx…
STAT+: At a defunct power station, the U.K. and Moderna celebrate a partnership meant to be an engine for science
LONDON — Back in the 1950s, Battersea Power Station, a towering brick structure on the…
STAT+: FDA rejects Intercept’s NASH drug, prompting a pivot
The Food and Drug Administration rejected Intercept Pharmaceuticals’ investigational treatment for NASH on Thursday, derailing…
STAT+: Medicare puts out new details for covering the Alzheimer’s drug Leqembi, as the health system readies for potential approval
WASHINGTON — The health care system is on the precipice of broad access to a treatment…
Listen: Messy PBM conflicts, debatable vaccines, & the future of flu season
Who’s watching the drug price watchmen? Are RSV vaccines too expensive? And is it finally…
FDA grants conditional approval to Sarepta’s gene therapy for Duchenne muscular dystrophy
The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for…
STAT+: The strategy behind the pharmaceutical industry’s flurry of lawsuits challenging drug pricing reform
WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere….
STAT+: European companies outline opposition to proposed overhaul of pharma policy
BRUSSELS — Leaders of European pharmaceutical companies on Wednesday said that a proposed overhaul of…
STAT+: After promising early data, gene therapy trial for Huntington’s takes puzzling turn
Last year, after a string of high-profile trial failures, the Huntington’s disease community got positive…
STAT+: One of biotech’s biggest financiers launches small-molecule startup, in spite of IRA’s looming shadow
It’s been nearly a year since Congress passed the Inflation Reduction Act, raising a chorus…
Scientists successfully unfroze rat organs and transplanted them — a ‘historic’ step that could someday transform transplant medicine
The rat kidney was peculiarly beautiful — an edgeless viscera about the size of a…
STAT+: Top federal lobbyist at PhRMA leaves
WASHINGTON — The top federal lobbyist for the brand drug lobby PhRMA is leaving, two…
STAT+: Exact Sciences touts accuracy of updated Cologuard cancer test, but experts want more data
An updated version of Exact Sciences’ stool-based colorectal cancer screening test detected cancer accurately in…
STAT+: Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal
Eli Lilly said Tuesday that it will purchase DICE Therapeutics, a small company developing an…
STAT+: How drug pricing reforms are affecting Bayer’s investments
WASHINGTON — Pharma companies have long been warning Democrats’ drug pricing reforms could discourage investment in…
Listen: Biogen’s messy board, Laronde’s data problem, & the downside of a boom
Can unicorns survive without data? Did biotech get over its skis? And what is going…
STAT+: Instead of credible data, PDS Biotech delivers ‘results might get better, later’ promises
Tumor response rate is a common way to assess the efficacy of a cancer drug….
STAT+: Pharmalittle: A not-so-new Biogen?; ALS Association and 15 chapters part ways over organizational clashes
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Muzzled for years, vindicated MIT professor says fraud investigation into his lab did lasting damage
For three years, nine months, and one week, Ram Sasisekharan lived under a gag order….
.jpg)
STAT+: Biogen’s boardroom scandal saddles CEO with first crisis
This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive,…
STAT+: Moving past regulatory obstacles, Protagonist Therapeutics looks to pivotal trial for its rare blood disorder therapy
FRANKFURT, Germany — Protagonist Therapeutics has run into some speed bumps as it’s developed its…
STAT+: Biotech executive nominated to Biogen board is mother of director’s child, records show
Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the…
STAT+: The inside story of how data integrity issues roiled a biotech seen as ‘Moderna 2.0’
In February 2022, Diego Miralles, then-CEO of a buzzy new biotech called Laronde, gathered his…
STAT+: Novartis to buy Chinook Therapeutics, developer of kidney disease therapies, in $3.2 billion deal
LONDON — Novartis said on Monday it would purchase Chinook Therapeutics for $3.2 billion upfront,…
STAT+: Francis deSouza’s tenure at Illumina is a lesson in how not to handle CEO succession
The sudden resignation of Francis deSouza as the CEO of Illumina Sunday represents anything but…
Following board fight, Francis deSouza resigns as Illumina CEO
Just two weeks after surviving an activist investor’s attempt to oust him from Illumina’s board,…
STAT+: Kura Oncology highlights leukemia remission data as it enrolls larger trial
FRANKFURT — A genetically targeted cancer drug from Kura Oncology has helped put more patients’…
STAT+: FDA panel unanimously endorses Eisai’s Alzheimer’s drug
Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding…
STAT+: Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy
FRANKFURT — Even as other cutting-edge genetic therapies for sickle cell disease move closer to…
.jpg)
STAT+: Updated data show long-term benefits of CRISPR treatment for sickle cell, beta thalassemia
FRANKFURT — Updated results released Friday highlighted the lasting benefits of a CRISPR-based medicine for…
STAT+: Tracking the FDA advisory panel on Eisai and Biogen’s treatment for Alzheimer’s disease
The Food and Drug Administration is convening a meeting of outside experts on Friday to…